Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.

about

Emerging formats for next-generation antibody drug conjugates.Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion.

P2860

Q38386705-29F3F5AC-4CB5-4B6D-9111-A632B13736C7 Q38738155-4F6825A5-1F70-4C99-8746-284EE738BD40 Q41966465-B12C4441-312F-4746-8D37-974A545C9AFE

P2860

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.

Item

http://www.wikidata.org/entity/Q39310345

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Targeting HER2-positive cancer ...... ovel antibody-drug conjugates.

@en

Targeting HER2-positive cancer ...... ovel antibody-drug conjugates.

@nl

type

Item

label

Targeting HER2-positive cancer ...... ovel antibody-drug conjugates.

@en

Targeting HER2-positive cancer ...... ovel antibody-drug conjugates.

@nl

prefLabel

Targeting HER2-positive cancer ...... ovel antibody-drug conjugates.

@en

Targeting HER2-positive cancer ...... ovel antibody-drug conjugates.

@nl

P1476

Targeting HER2-positive cancer ...... ovel antibody-drug conjugates.

@en

P2093

Antonio Recio

http://www.w3.org/2001/XMLSchema#string

Beverly A Teicher

http://www.w3.org/2001/XMLSchema#string

Cecile Rouleau

http://www.w3.org/2001/XMLSchema#string

Dennis Lovett

http://www.w3.org/2001/XMLSchema#string

Diego A Gianolio

http://www.w3.org/2001/XMLSchema#string

Hildegard M Kramer

http://www.w3.org/2001/XMLSchema#string

James E Stefano

http://www.w3.org/2001/XMLSchema#string

James Goebel

http://www.w3.org/2001/XMLSchema#string

Michelle Busch

http://www.w3.org/2001/XMLSchema#string

Paul Wolstenholme-Hogg

http://www.w3.org/2001/XMLSchema#string

P2860

Microtubules as a target for anticancer drugs

Arming antibodies: prospects and challenges for immunoconjugates.

The prolyl oligopeptidase family.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Microtubule-associated proteins as targets in cancer chemotherapy.

Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.

Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity

Newer cytotoxic agents: attacking cancer broadly.

Antibody-drug conjugates for cancer therapy.

P2888

s00280-012-1925-8

P304

439-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-012-1925-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22821053

http://www.w3.org/2001/XMLSchema#string

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.

about

P2860

P2860

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698